Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Open-label, Randomized, Prospective, Interventional Post-authorization Efficacy and Safety Study of Mirabegron 50 mg and 25 mg for the Treatment of Overactive Bladder in Chinese Subjects

NCT04562090 is registered in ClinicalTrials.gov with Astellas Pharma China, Inc. as lead sponsor.

NCT NCT04562090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04562090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Open-label, Randomized, Prospective, Interventional Post-authorization Efficacy and Safety Study of Mirabegron 50 mg and 25 mg for the Treatment of Overactive Bladder in Chinese Subjects
Lead sponsor
Astellas Pharma China, Inc.
Phase
Phase 4
Overall status
Completed
Start date
January 6, 2021
Completion date
March 30, 2022
Enrollment
249 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder (oab), urge incontinence